Selank – Nasal spray

Selank Nasal Spray is a compounded, investigational neuroactive peptide preparation primarily studied for anxiolytic, neuroprotective, cognitive-enhancing, and immunomodulatory effects. Typical pharmacy compounding produces a nasal spray at 1 mg/mL for both clinical research and off-label therapeutic use in anxiety disorders, cognitive dysfunction, and other neuropsychiatric or immunological indications.

Structure: Selank is a synthetic analog of the endogenous tuftsin molecule, designed to enhance immune function and provide anxiolytic effects through GABA-A receptor modulation.

Structure: Selank is a synthetic analog of the endogenous tuftsin molecule, designed to enhance immune function and provide anxiolytic effects through GABA-A receptor modulation.

Selank’s mechanism of action involves positive allosteric modulation of gamma-aminobutyric acid type A (GABA-A) receptors in the brain. By enhancing the affinity and activity of endogenous GABA at these inhibitory receptors, Selank promotes anxiolytic and calming effects without significant sedation or dependence. It also alters the gene expression involved in the GABAergic system, and secondarily regulates neuroimmune gene networks—including effects on cytokine balance, monoamine neurotransmitters (serotonin, dopamine), and antiviral pathways. This multi-modal action underlies both its rapid anxiolytic properties and potential cognitive and immune benefits.

Nootropic Effects: Demonstrates positive impacts on memory consolidation and learning processes through modulation of brain-derived neurotrophic factor (BDNF).

Nootropic Effects: Demonstrates positive impacts on memory consolidation and learning processes through modulation of brain-derived neurotrophic factor (BDNF).

Selank exhibits an excellent tolerability profile in clinical and preclinical studies. Rare adverse effects include mild nasal or throat irritation, transient headache, or dizziness. Allergic reactions are exceedingly rare, and there is no evidence for sedation, dependence, withdrawal, or systemic toxicity in published research. Monitoring is recommended for local irritation, psychological changes, or unexpected systemic effects.

Clinical Safety Profile: Studies demonstrate effects similar to low-dose tranquilizers but without the adverse effects characteristic of benzodiazepines, including amnesia, withdrawal symptoms, and dependence (PMC4757669).

Clinical Safety Profile: Studies demonstrate effects similar to low-dose tranquilizers but without the adverse effects characteristic of benzodiazepines, including amnesia, withdrawal symptoms, and dependence (PMC4757669).

Contraindications: Hypersensitivity to Selank or excipients; do not use in pregnancy, lactation, or pediatric populations due to insufficient data. Precautions: Use caution in patients on other CNS-active drugs; human safety data, though encouraging, remain limited and off-label use should involve specialist oversight.

Selank is supplied as a nasal spray solution at a standard concentration of 1 mg/mL. Administer by spraying 1–2 sprays per nostril, once or twice daily as directed. Initial protocols often recommend a total daily dose of approximately 1 mg, divided between doses. Treatment cycles range from 10–14 days but can be individualized based on clinical need and patient response. For accurate delivery, follow specific instructions from the compounding pharmacy. Dose titration may be required per physician guidance, especially for off-label or investigational use.